Lifecore Biomedical, Inc.

LFCR Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

6.38 0.06 −0.93%
Market cap
$244.1M
P/E
0.0×
Fwd P/E
−5.4×
Dividend yield
—
F-score
3/9
Altman Z
0.12
Beneish M
−3.15
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
201.15% 293.76% 0.00% (1,055.37%)

+8 more TTM periods

Piotroski F-Score
2 5 — 3
ROA
(19.32%) (17.13%) 0.00% (10.57%)
ROIC
(2.80%) (2.32%) 0.00% (3.95%)
Return on Tangible Assets
(24.16%) (21.79%) 0.00% (14.20%)
Average Days of Receivables
92.96 58.22 0.00 72.37
Free Cash Flow per Share
(0.13) 0.36 — 0.35
Free Cash Flow
(5.06) 13.50 — 13.17
Other line items

Show all line items

Columns are period end dates